Related Experiment Video

Updated: Aug 10, 2026

Technique of Subnormothermic Ex Vivo Liver Perfusion for the Storage, Assessment, and Repair of Marginal Liver Grafts
09:29

Technique of Subnormothermic Ex Vivo Liver Perfusion for the Storage, Assessment, and Repair of Marginal Liver Grafts

Published on: August 13, 2014

Enzyme replacement and beyond

R J Desnick1

  • 1Department of Human Genetics, Mount Sinai School of Medicine of New York University, New York 10029, USA. rjdesnick@mssm.edu

Journal of Inherited Metabolic Disease
|June 19, 2001
PubMed

Insights

Enzyme replacement therapy is a viable treatment for lysosomal storage diseases like Fabry disease. Clinical trials demonstrate the safety and efficacy of recombinant human alpha-galactosidase A (r-halphaGal A) therapy.

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Lysosomal storage diseases (LSDs) are a group of inherited metabolic disorders.
  • Enzyme replacement therapy (ERT) has emerged as a successful treatment for some LSDs, notably Gaucher disease.
  • Fabry disease, caused by alpha-galactosidase A (alpha-Gal A) deficiency, is a target for new therapeutic strategies.

Purpose of the Study:

  • To present the drug development process for recombinant human alpha-galactosidase A (r-halphaGal A) as an ERT for Fabry disease.
  • To highlight the regulatory pathways, including orphan drug and fast track designations, that can accelerate therapy development for rare diseases.

Main Methods:

  • Preclinical studies using a 'Fabry mouse' model to evaluate r-halphaGal A.
  • Clinical trials, including Phase 1/2, Phase 3, and Phase 3 extension studies, to assess safety and efficacy.
  • Regulatory review processes for new drug approvals.

Main Results:

  • Preclinical studies in the Fabry mouse model provided a basis for clinical development.
  • Clinical trials demonstrated the safety and efficacy of r-halphaGal A replacement therapy.
  • The drug development process adhered to rigorous regulatory standards.

Conclusions:

  • Enzyme replacement therapy with r-halphaGal A is a safe and effective treatment for Fabry disease.
  • The development process exemplifies the application of regulatory pathways for rare inherited metabolic diseases.
  • ERT offers a promising therapeutic option for patients with Fabry disease and potentially other LSDs.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...